There are inequities in all areas of healthcare.
Diverse Health Hub collects relevant and meaningful content for five therapeutic areas. Our focus allows us to organize and deliver health equity information regarding what is most important to you as a patient, patient care team member, or a healthcare provider.
Breast cancer survival and screening rates have improved significantly. However, incidence rates are higher among women of color and more often than not, these women are diagnosed at a later stage.
Kidney cancer is a disease involving the abnormal and uncontrolled growth of cells in the kidneys. Renal cell carcinoma (RCC), represents about 85% of kidney cancers. Kidney cancer incidence and mortality rates are twice as high in men as in women. Rare kidney cancer health disparities afflict racial/ethnic groups with higher death rates from lack of access and disease awareness.
Sickle cell disease is a blood disorder caused by mutation, and it affects millions of people. Sickle cell is more common among people of certain ancestries, including those of African, Caribbean, Middle Eastern, Eastern Mediterranean, and Asian descent.
Multiple myeloma is a blood disorder that begins in the plasma cells. Studies have shown that minority populations are at an elevated risk for myeloma, yet are under-represented in research.
Clinical trials are responsible for numerous advancements in medicine and cures for a multitude of diseases. Evidence has shown that Hispanics, Asians and African-Americans are not adequately represented in clinical trials in the US.
Despite positive trends nationwide in prostate cancer health outcomes, incidence and mortality disparities still exist between Black and white men. During 2011-2015, the average annual prostate cancer incidence rate for Black men was 76% higher when compared to white men across the country.